View in EDS HTML Full Text PDF Full Text

Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination.

Saved in:
Bibliographic Details
Title: Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination.
Authors: Kister, Ilya1 (AUTHOR) ilya.kister@nyulangone.org, Curtin, Ryan2 (AUTHOR), Piquet, Amanda L.3 (AUTHOR), Borko, Tyler3 (AUTHOR), Pei, Jinglan4 (AUTHOR), Banbury, Barbara L5 (AUTHOR), Bacon, Tamar E.1 (AUTHOR), Kim, Angie1 (AUTHOR), Tuen, Michael6 (AUTHOR), Velmurugu, Yogambigai2 (AUTHOR), Nyovanie, Samantha2 (AUTHOR), Selva, Sean3 (AUTHOR), Samanovic, Marie I.6 (AUTHOR), Mulligan, Mark J.6 (AUTHOR), Patskovsky, Yury2 (AUTHOR), Priest, Jessica4 (AUTHOR), Cabatingan, Mark4 (AUTHOR), Winger, Ryan C.4 (AUTHOR), Krogsgaard, Michelle2 (AUTHOR) michelle.krogsgaard@nyulangone.org, Silverman, Gregg J.7 (AUTHOR) gregg.silverman@nyulangone.org
Source: Annals of Clinical & Translational Neurology. Jul2024, Vol. 11 Issue 7, p1750-1764. 15p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:23289503
DOI:10.1002/acn3.52081